Matrix Metalloproteinase-26 Is Associated with Estrogen-Dependent Malignancies and Targets α1-Antitrypsin Serpin
Open Access
- 1 December 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (23) , 8657-8665
- https://doi.org/10.1158/0008-5472.can-04-3019
Abstract
Proteases exert control over cell behavior and affect many biological processes by making proteolytic modification of regulatory proteins. The purpose of this paper is to describe novel, important functions of matrix metalloproteinase (MMP)-26. α1-Antitrypsin (AAT) is a serpin, the primary function of which is to regulate the activity of neutrophil/leukocyte elastase. Insufficient antiprotease activity because of AAT deficiency in the lungs is a contributing factor to early-onset emphysema. We recently discovered that AAT is efficiently cleaved by a novel metalloproteinase, MMP-26, which exhibits an unconventional PH81CGVPD Cys switch motif and is autocatalytically activated in cells and tissues. An elevated expression of MMP-26 in macrophages and polymorphonuclear leukocytes supports the functional role of MMP-26 in the AAT cleavage and inflammation. We have demonstrated a direct functional link of MMP-26 expression with an estrogen dependency and confirmed the presence of the estrogen-response element in the MMP-26 promoter. Immunostaining of tumor cell lines and biopsy specimen microarrays confirmed the existence of the inverse correlations of MMP-26 and AAT in cells/tissues. An expression of MMP-26 in the estrogen-dependent neoplasms is likely to contribute to the inactivation of AAT, to the follow-up liberation of the Ser protease activity, and because of these biochemical events, to promote matrix destruction and malignant progression. In summary, we hypothesize that MMP-26, by cleaving and inactivating the AAT serpin, operates as a unique functional link that regulates a coordinated interplay between Ser and metalloproteinases in estrogen-dependent neoplasms.Keywords
This publication has 44 references indexed in Scilit:
- Matrix metalloproteinase-26 (Matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancerGynecologic Oncology, 2004
- Endometase/Matrilysin-2 in Human Breast Ductal Carcinoma in Situ and Its Inhibition by Tissue Inhibitors of Metalloproteinases-2 and -4Cancer Research, 2004
- A review and comparison of the murine α1-antitrypsin and α1-antichymotrypsin multigene clusters with the human clade A serpinsGenomics, 2003
- Matrix metalloproteinase‐26 is expressed in human endometrium but not in endometrial carcinomaCancer, 2002
- Peptide Substrate Specificities and Protein Cleavage Sites of Human Endometase/Matrilysin-2/Matrix Metalloproteinase-26Journal of Biological Chemistry, 2002
- Unconventional Activation Mechanisms of MMP-26, a Human Matrix Metalloproteinase with a Unique PHCG XXD Cysteine-switch MotifJournal of Biological Chemistry, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- α1-Antitrypsin Deficiency: Biological Answers to Clinical QuestionsThe Lancet Healthy Longevity, 2001
- Substrate Hydrolysis by Matrix Metalloproteinase-9*Journal of Biological Chemistry, 2001
- Human Colon Carcinoma Cells Synthesize and Secrete α1-Proteinase InhibitorBiological Chemistry Hoppe-Seyler, 1996